John Oyler Sells 3,693 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 3,693 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $265.55, for a total transaction of $980,676.15. Following the completion of the sale, the chief executive officer directly owned 2,043 shares in the company, valued at approximately $542,518.65. The trade was a 64.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Oyler also recently made the following trade(s):

• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total value of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The shares were sold at an average price of $270.56, for a total value of $1,336,566.40.

BeOne Medicines Stock Performance

NASDAQ ONC opened at $270.15 on Friday. The firm has a 50-day moving average of $295.32 and a 200-day moving average of $312.15. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The stock has a market cap of $29.64 billion, a PE ratio of 60.44 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $239.25 and a 52-week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The company had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. On average, sell-side analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Wolfe Research began coverage on BeOne Medicines in a research note on Friday, March 27th. They issued an “outperform” rating and a $340.00 price target for the company. Leerink Partners raised their target price on shares of BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Morgan Stanley restated an “overweight” rating and issued a $395.00 target price on shares of BeOne Medicines in a research report on Thursday, May 7th. Royal Bank Of Canada upped their price target on shares of BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research note on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $390.00.

Institutional Investors Weigh In On BeOne Medicines

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Empowered Funds LLC bought a new position in BeOne Medicines in the 1st quarter valued at approximately $201,000. Bank of America Corp DE increased its holdings in shares of BeOne Medicines by 7.0% during the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock worth $120,354,000 after buying an additional 26,441 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in shares of BeOne Medicines in the 1st quarter valued at $3,475,000. EverSource Wealth Advisors LLC boosted its holdings in shares of BeOne Medicines by 16.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 369 shares of the company’s stock valued at $110,000 after acquiring an additional 52 shares in the last quarter. Finally, Royal Bank of Canada boosted its holdings in shares of BeOne Medicines by 3.5% during the 1st quarter. Royal Bank of Canada now owns 70,391 shares of the company’s stock valued at $20,905,000 after acquiring an additional 2,399 shares in the last quarter. 48.55% of the stock is owned by institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.